

Zydus Cadila receives final approval from USFDA for Meclizine Hydrochloride Tablets

Ahmedabad, June 24, 2020

Zydus Cadila has received final approval from the USFDA to market Meclizine Hydrochloride Tablets (US RLD: Antivert™ Tablets) in the strengths of 12.5 mg and 25 mg.

Meclizine is an antihistamine that is used to prevent and treat nausea, vomiting, and dizziness caused by motion sickness. It may also be used to reduce dizziness and loss of balance (vertigo) caused by inner ear problems. The drug will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.

The group now has 292 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally.
